Intra-Cellular Therapies, Inc.
ITCIDelisted Apr 2, 2025- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001567514
Intra-Cellular Therapies, Inc. was delisted on Apr 2, 2025; its insiders filed their last Form 4 on Apr 2, 2025; 395 institutions reported holding it in 13F filings for Q1 2025, worth $13.6B in total; Soros Fund Management was the only superinvestor holding it.
13F holders, Q4 2024
Institutional positions in Intra-Cellular Therapies, Inc. as of Dec 31, 2024. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 387
- +39 vs. Q3 2024
- Shares held
- 96.8M
- +437.4K (+0.5%) vs. Q3 2024
- Total value
- $8.08B
- +$1.03B (+14.6%) vs. Q3 2024
- New holders
- 69
- 133 more added
- Sold out
- 30
- 138 more reduced
8 institutions that held it in Q3 2024 haven't filed for Q4 2024 yet. Not filing isn't selling, so they aren't counted as sold out or in the changes above.
Compare with Q3 2024: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ITCI on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 1 | $2.54K |
| Q1 2026 | 1 | $2.54K |
| Q4 2025 | 1 | $2.54K |
| Q3 2025 | 1 | $2.54K |
| Q2 2025 | 4 | $4.15M |
| Q1 2025 | 395 | $13.6B |
| Q4 2024 | 387 | $8.08B |
| Q3 2024 | 356 | $7.12B |
| Q2 2024 | 376 | $6.62B |
| Q1 2024 | 346 | $6.15B |
| Q4 2023 | 335 | $6.42B |
| Q3 2023 | 294 | $4.54B |
| Q2 2023 | 288 | $5.34B |
| Q1 2023 | 274 | $4.55B |
| Q4 2022 | 283 | $4.41B |
| Q3 2022 | 274 | $3.89B |
| Q2 2022 | 266 | $4.65B |
| Q1 2022 | 241 | $4.94B |
| Q4 2021 | 208 | $3.60B |
| Q3 2021 | 181 | $2.56B |
| Q2 2021 | 187 | $2.74B |
| Q1 2021 | 170 | $2.30B |
Institutions, Q4 2024
Shares, value and share of portfolio for each institution holding Intra-Cellular Therapies, Inc.; share changes are against Q3 2024.